Ulobetasol
Clinical data | |
---|---|
Trade names | Ultravate |
Other names | (6S,8S,9S,10S,11S,13S,14S,16S,17R)-17-(2-Chloroacetyl)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one, halobetasol (USAN US) |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a601060 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H27ClF2O4 |
Molar mass | 428.90 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Ulobetasol (INN) or halobetasol (USAN) is a corticosteroid used to treat psoriasis.[1][2] It is a class I corticosteroid under the US classification and a group III corticosteroid under international classification, the most potent group of such drugs.[3][4]
Ulobetasol propionate is usually supplied as a 0.05% topical cream.[1] Ulobetasol is the strongest topical steroid available.[citation needed] It is also sold with tazarotene with 0.01% halobetasol and 0.045% tazarotene as a lotion branded as Duobrii (Bausch Health).
It is available as a generic medication.[5]
References
- ^ a b "Ultravate product monograph" (PDF). Retrieved 2021-01-04.
- ^ DrugBank DB00596 . Retrieved 2020-01-04.
- ^ Pearce DJ, Spencer L, Hu J, Balkrishnan R, Fleischer AB, Feldman SR (July 2004). "Class I topical corticosteroid use by psoriasis patients in an academic practice". The Journal of Dermatological Treatment. 15 (4): 235–8. doi:10.1080/09546630410033745. PMID 15764038. S2CID 2757493.
- ^ ATC code D07AC21 (WHO). Retrieved 2020-01-04.
- ^ "Ulobetasol international". Drugs.com. 10 August 2020. Retrieved 15 August 2020.
External links
- "Halobetasol". Drug Information Portal. U.S. National Library of Medicine.
- "Halobetasol propionate". Drug Information Portal. U.S. National Library of Medicine.
- halobetasol at the U.S. National Library of Medicine Medical Subject Headings (MeSH)